Jingyan Wang

Jingyan Wang

Auto-generated profile, based on publicly available information

Jingyan Wang

Center for Drug Evaluation and Research, Silver Spring, Maryland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
PPPoghni A. Peri-Okonny
Poghni A. Peri-Okonny
JWJingyan Wang
Jingyan Wang
KGKensey L. Gosch
Kensey L. Gosch
MPManesh R. Patel
Manesh R. Patel
MSMehdi H. Shishehbor
Mehdi H. Shishehbor
KSKim G. Smolderen
Kim G. Smolderen
Background: Understanding minimum clinically important differences (MCID) in patient-reported outcomes is essential in interpreting the magnitude of changes in these measures. No MCID from patients’ perspectives has ever been published for peripheral artery disease–specific health status assessment tools. The Peripheral Artery Questionnaire (PAQ) is a commonly used, validated peripheral artery disease–specific health status instrument for which we sought to prospectively establish its MCID from patients’ perspectives. Methods and Results: Patients presenting to vascular clinics with new or worsened claudication in the US cohort of the PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories) registry who completed baseline and follow-up PAQ assessments along with the Global Assessment of Functioning scale were included. Mean change in PAQ summary scores from 3- to 6-month follow-up was calculated according to Global Assessment of Functioning category. MCID was defined as the mean difference in scores between those with small improvement or deterioration and those with no change. Multivariable linear regression was used to provide an MCID estimate after adjusting for patients’ 3-month PAQ score. Of the 483 patients who completed the Global Assessment of Functioning score at 6 months and who had available 3- and 6-month PAQ assessments, the mean age was 69 years, 42% were female, and 71% were White. The MCIDs for PAQ summary scale improvement and worsening were 8.7 (2.9–14.5) and −11.0 (−18.6 to −3.3), respectively. After multivariable adjustment, these were 8.9 (3.0–14.8) and −11.2 (−18.2 to −4.2), respectively. There was no significant interaction between treatment (invasive versus noninvasive) and Global Assessment of Functioning response ( P =0.75). Conclusions: In patients with new or worsened claudication, a 10-point change in PAQ summary score represents an MCID. This estimate needs external validation and may inform the interpretation of PAQ scores when used as outcomes in clinical trials or in routine clinical care. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01419080.

27 June 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
RLRobert Q. Le
Robert Q. Le
KGKamar Godder
Kamar Godder
JWJingyan Wang
Jingyan Wang
JCJustin S. Collazo
Justin S. Collazo
RKRobyn Konicki
Robyn Konicki
RCR. Angelo de Claro
R. Angelo de Claro
On August 14, 2024, the FDA approved axatilimab, a colony-stimulating factor-1 receptor–blocking antibody, for chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kilograms (kg). Approval was based on the results of the AGAVE-201 Study (NCT04710576), which included a cohort of 79 patients with chronic GVHD treated with axatilimab 0.3 mg/kg administered intravenously every 2 weeks in an open-label, single-arm cohort. Efficacy was determined by the overall response rate through cycle 7 day 1, which included complete response and partial response according to the 2014 NIH consensus criteria, and the durability of response. The overall response rate through cycle 7 day 1 was 75% [95% confidence interval (CI), 64–84]; all responses were partial response. The median duration of response was 1.9 months (95% CI, 1.6–3.5), but 60% (95% CI, 43–74) of responding patients remained alive without new systemic therapy for at least 12 months from response. The common adverse reactions included infection, increased transaminases, decreased phosphate, decreased hemoglobin, musculoskeletal pain, increased lipase, fatigue, increased amylase, increased calcium, increased creatine phosphokinase, increased alkaline phosphatase, nausea, headache, diarrhea, cough, fever, and dyspnea. FDA issued a post-market requirement to evaluate safety with long-term use.

11 March 2022 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
WBWilliam B. Borden
William B. Borden
JWJingyan Wang
Jingyan Wang
PJPhilip Jones
Philip Jones
YTYuanyuan Tang
Yuanyuan Tang
JCJohanna Contreras
Johanna Contreras
TMThomas M. Maddox
Thomas M. Maddox
Background: The Million Hearts Cardiovascular Disease Risk Reduction Model provides financial incentives for practices to lower 10-year atherosclerotic cardiovascular disease (ASCVD) risk for high-risk (ASCVD ≥30%) Medicare patients. To estimate average practice-level ASCVD risk reduction, we applied optimal trial outcomes to a real-world population with high ASCVD risk. Methods: This study uses observational registry data from the National Cardiovascular Data Registry Practice Innovation and Clinical Excellence Registry from January 2013 to June 2016. We modeled ASCVD risk reductions using historical clinical trial data (reducing cholesterol by 26.5%, reducing systolic blood pressure by 10.9%, reducing smoking rates by 21.8%) the average reduction in ASCVD risk associated with individual and combined risk factor modifications, and then percentage of practices achieving the various incentive thresholds for the Million Hearts Model. Results: The final study population included 135 166 patients, with 16 248 (12.0%) with 10-year ASCVD risk of ≥30%, but without existing ASCVD. The mean 10-year ASCVD risk was 41.9% (±1 SD of 11.6). Using risk factor reductions from clinical trials, lowering cholesterol, blood pressure, and smoking rates reduced 10-year ASCVD risk by 3.3% (±3.1), 6.3% (±1.1) and 0.5% (±1.3), respectively. Combining all 3 reductions resulted in a 9.7% (±3.6) reduction, with 67 (27.0%) of practices achieving a patient-level average 10-year ASCVD risk reduction of ≥10%, 181 (73.0%) achieving a 2 to 10% reduction, and no practice achieving <2% reduction. Conclusions: In cardiology practices, about 1 out of 8 patients have a 10-year ASCVD risk ≥30% and qualify as high risk in the Million Hearts Model. If practices target the three main modifiable risk factors and achieve reductions similar to clinical trial results, ASCVD risk could be substantially lowered and all practices could receive incentive payments. These findings support the potential benefit of the Million Hearts Model and provide guidance to participating practices.

2 September 2025
Verified
Other
Open access
RLRobert Q. Le
Robert Q. Le
KGKamar Godder
Kamar Godder
JWJingyan Wang
Jingyan Wang
JCJustin S. Collazo
Justin S. Collazo
RKRobyn Konicki
Robyn Konicki
RCR. Angelo de Claro
R. Angelo de Claro
On August 14, 2024, the FDA approved axatilimab, a colony-stimulating factor-1 receptor–blocking antibody, for chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kilograms (kg). Approval was based on the results of the AGAVE-201 Study (NCT04710576), which included a cohort of 79 patients with chronic GVHD treated with axatilimab 0.3 mg/kg administered intravenously every 2 weeks in an open-label, single-arm cohort. Efficacy was determined by the overall response rate through cycle 7 day 1, which included complete response and partial response according to the 2014 NIH consensus criteria, and the durability of response. The overall response rate through cycle 7 day 1 was 75% [95% confidence interval (CI), 64–84]; all responses were partial response. The median duration of response was 1.9 months (95% CI, 1.6–3.5), but 60% (95% CI, 43–74) of responding patients remained alive without new systemic therapy for at least 12 months from response. The common adverse reactions included infection, increased transaminases, decreased phosphate, decreased hemoglobin, musculoskeletal pain, increased lipase, fatigue, increased amylase, increased calcium, increased creatine phosphokinase, increased alkaline phosphatase, nausea, headache, diarrhea, cough, fever, and dyspnea. FDA issued a post-market requirement to evaluate safety with long-term use.